The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indicator for liver transplantation. A Markov model was used to forecast NAFLD disease progression. Incidence of NAFLD was based on historical and projected changes in adult prevalence of obesity and type 2 diabetes mellitus (DM). Assumptions were derived from published literature where available and validated using national surveillance data for incidence of NAFLD‐related HCC. Projected changes in NAFLD‐related cirrhosis, advanced liver disease, and liver‐related mortality were quantified through 2030. Prevalent NAFLD cases are forecasted to increase 21%, from 83.1 million (2015) to 100.9 million (2030), while prevalent NASH cases will increase 63% from 16.52 million to 27.00 million cases. Overall NAFLD prevalence among the adult population (aged ≥15 years) is projected at 33.5% in 2030, and the median age of the NAFLD population will increase from 50 to 55 years during 2015‐2030. In 2015, approximately 20% of NAFLD cases were classified as NASH, increasing to 27% by 2030, a reflection of both disease progression and an aging population. Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases. Liver deaths will increase 178% to an estimated 78,300 deaths in 2030. During 2015‐2030, there are projected to be nearly 800,000 excess liver deaths. Conclusion: With continued high rates of adult obesity and DM along with an aging population, NAFLD‐related liver disease and mortality will increase in the United States. Strategies to slow the growth of NAFLD cases and therapeutic options are necessary to mitigate disease burden. (H epatology 2018;67:123‐133).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2739 · Cited by 200
RetractedDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationAngulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Self-citationByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Self-citationNonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Self-citationNon-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
Self-citationMcPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., & Day, C. P. (2010) · Gut · doi:10.1136/gut.2010.216077 · Cited by 946
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · cited 6×
“8% reported in the literature for 2004-2009 (1).”
BackgroundResultInfluentialSelf-citationLazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Wong, R. J., Cheung, R., & Ahmed, A. (2014) · Hepatology · doi:10.1002/hep.26986 · Cited by 723
Sanyal, A. J., Banas, C., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Heuman, D., Coterrell, A., Fisher, R. A., et al. (2006) · Hepatology · doi:10.1002/hep.21103 · Cited by 522
Self-citationPortillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J. M., Saracco, G., Adams, L. A., Charatcharoenwitthaya, P., Topping, J. H., Bugianesi, E., et al. (2011) · Hepatology · doi:10.1002/hep.24491 · Cited by 450
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, S. F., Henley, J. S., Cucinelli, J. E., & McGlynn, K. A. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.11 · Cited by 429
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study
Lazo, M., Hernaez, R., Bonekamp, S., Kamel, I. R., Brancati, F. L., Guallar, E., & Clark, J. M. (2011) · BMJ · doi:10.1136/bmj.d6891 · Cited by 395
Koehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Population-based risk factors and resource utilization for HCC: US perspective
Sanyal, A., Poklepovic, A., Moyneur, E., & Barghout, V. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.506375 · Cited by 312
Self-citationStepanova, M., Rafiq, N., Makhlouf, H., Agrawal, R., Kaur, I., Younoszai, Z., McCullough, A., Goodman, Z., & Younossi, Z. M. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2743-5 · Cited by 301
Self-citationKabbany, M. N., Selvakumar, P. K. C., Watt, K., Lopez, R., Akras, Z., Zein, N., Carey, W., & Alkhouri, N. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.5 · Cited by 242
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Kanwal, F., Kramer, J. R., Duan, Z., Yu, X., White, D., & El-Serag, H. B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.010 · Cited by 159
The current economic burden of cirrhosis.
Neff, G. W., Duncan, C. W., & Schiff, E. R. (2011) · Europe PMC (PubMed Central) · Cited by 149
Whalley, S. A., Puvanachandra, P., Desai, A. M., & Kennedy, H. J. (2007) · Clinical Medicine · doi:10.7861/clinmedicine.7-2-119 · Cited by 124
Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
Younossi, Z. M., & Henry, L. L. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0316-5 · Cited by 92
Self-citationGround, K. E. (1982) · PubMed · Cited by 70
Goossens, N., Hoshida, Y., Song, W., Jung, M. K., Morel, P., Nakagawa, S., Zhang, B., Frossard, J., Spahr, L., Friedman, S. L., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.010 · Cited by 62
Gregg, E. W., Boyle, J. P., Thompson, T. J., Barker, L. E., Albright, A. L., & Williamson, D. F. (2013) · Population Health Metrics · doi:10.1186/1478-7954-11-18 · Cited by 45
Nonalcoholic fatty liver disease (NAFLD): Is it really a serious condition?
Wattacheril, J. J., & Chalasani, N. (2012) · Hepatology · doi:10.1002/hep.26031 · Cited by 37
Nonalcoholic fatty liver disease
Grant, L. M., & Lisker‐Melman, M. (2004) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32100-3 · Cited by 34
Kim, Y. S., Jung, E. S., Hur, W., Bae, S. H., Choi, J. Y., Song, M. J., Kim, C. W., Jo, S. H., Lee, C. D., Lee, Y. S., et al. (2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.2.120 · Cited by 33
Rinella, M. E. (2011) · Hepatology · doi:10.1002/hep.24634 · Cited by 20
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationBurden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Metadata
- Authors
- Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J.
- Venue
- Hepatology
- Published
- 2017-12-01
- Volume
- 67
- Issue
- 1
- Pages
- 123-133
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2744982526
- Cited by
- 2,399
- References
- 46
- FWCI
- 97.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.